Biocon Biologics and Viatris Receive EC’s Approval for Kixelle (biosimilar, insulin aspart) for Diabetes Mellitus

February 15, 2021 Auto Bot approval, Biocon Biologics, Biosimilars, EC, Receive, Viatris 0

Shots:

  • The EC approval follows CHMP’s positive recommendation for Kixelle to treat DM in adults, adolescents, and children aged ≥1yr. The biosimilar has been approved as a 100 units/ml solution for injection in vial & pre-filled pen presentations
  • The EC’s CMA is valid in all EU Member States as well as in the EEA countries including Iceland, Liechtenstein, and Norway
  • The approval will allow affordable access to a rapid-acting insulin analog for people with diabetes in the EU

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Business Standard

The post Biocon Biologics and Viatris Receive EC’s Approval for Kixelle (biosimilar, insulin aspart) for Diabetes Mellitus first appeared on PharmaShots.